ApprovalTrail

Approval · Notice of Compliance 28079 · 2022

CLOZARIL: Notice of Compliance 28079

Issued May 4, 2022

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
28079
Date
May 4, 2022
Company
Hls Therapeutics IncEtobicoke, Ontario, Canada
Product type
Prescription Pharmaceutical
Submission
Supplement to a New Drug Submission (SNDS), supplement
Submission class
Other
Reason
Update to the Product Monograph with new safety information.

Products in this notice

BrandDINStatus today
CLOZARILNot yet assigned—

Medicinal ingredients